Log In
Print
BCIQ
Print
Print this Print this
 

Jaquinus, Xeljanz (tofacitinib) (CP-690,550) (formerly tasocitinib)

Also known as: formerly CP-690550

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionOral pan-Janus kinase (JAK) inhibitor
Molecular Target Janus kinase-3 (JAK-3) ; Janus kinase-1 (JAK-1)
Mechanism of ActionJanus kinase-3 (JAK-3) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today